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With the recent advances in biological structural electron microscopy (EM),
protein structures can now be obtained by cryo-EM and single-particle analysis
at resolutions that used to be achievable only by crystallographic or NMR
methods. We have explored their application to study protein–ligand inter-
actions using the human 20S proteasome, a well established target for cancer
therapy that is also being investigated as a target for an increasing range of other
medical conditions. The map of a ligand-bound human 20S proteasome served
as a proof of principle that cryo-EM is emerging as a realistic approach for more
general structural studies of protein–ligand interactions, with the potential
benefits of extending such studies to complexes that are unfavourable to other
methods and allowing structure determination under conditions that are closer
to physiological, preserving ligand specificity towards closely related binding
sites. Subsequently, the cryo-EM structure of the Plasmodium falciparum 20S
proteasome, with a new prototype specific inhibitor bound, revealed the
molecular basis for the ligand specificity towards the parasite complex, which
provides a framework to guide the development of highly needed new-
generation antimalarials. Here, the cryo-EM analysis of the ligand-bound human
and P. falciparum 20S proteasomes is reviewed, and a complete description of
the methods used for structure determination is provided, including the strategy
to overcome the bias orientation of the human 20S proteasome on electron-
microscope grids and details of the icr3d software used for three-dimensional
reconstruction.
1. Introduction
The growing understanding of the intricate mechanisms
underlying cellular function, and how these are disrupted in
disease, allows the identification of specific molecular targets
that can be modulated by chemical compounds with the
potential to be developed as next-generation drugs for clinical
use. The proteasome is a large protease complex that is
essential in all eukaryotes. It not only contributes to overall
proteostasis, but also plays a critical role in the highly regu-
lated ATP-dependent degradation of specific ubiquitin-tagged
proteins, the removal of which triggers fundamental mechan-
isms such as cell-cycle progression and apoptosis. The
proteasome comprises a proteolytic core, the 20S proteasome,
which encloses the proteolytic active sites (Lowe et al., 1995;
Groll et al., 1997). In eukaryotes, the 20S proteasome is
formed by hetero-heptameric rings of homologous  and 
subunits arranged as a twofold-symmetric (1–7)(1–7)(1–7)(1–7)
barrel-shaped stack (Groll et al., 1997; Unno et al., 2002;
Harshbarger et al., 2015). The active sites of the proteolytic
subunits, 1, 2 and 5, are located within the inner cavity of
the 20S proteasome and have distinct amino-acid sequence-
cleavage specificities, namely caspase-like, trypsin-like and
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chymotrypsin-like, respectively (Heinemeyer et al., 1997).
Variant forms of the proteasome can be found in higher
eukaryotes (Kniepert & Groettrup, 2014; Dahlmann, 2016).
These include the immunoproteasome, in which the active
subunits of the constitutive proteasome are replaced by the
interferon -induced 1i, 2i and 5i counterparts (Kuck-
elkorn et al., 1995; Groettrup et al., 1996), which are critical for
the generation of antigenic peptides for major histocompat-
ibility class I presentation. Other proteasome variants include
the thymoproteasome (Murata et al., 2007), which is found
in the thymic cortex, where the 5t subunit variant is
expressed and incorporated into the proteasome together with
1i and 2i, and the spermatoproteasome, a mammalian
variant in which the constitutive 4 subunit is replaced by
testis-specific 4s (Yuan et al., 1996). The 20S proteasome on
its own provides limited access to its active sites. Accordingly,
the 20S proteasome has only limited proteolytic activity
towards small peptides and disordered proteins (Groll et al.,
2000), and its full activation requires the association of regu-
latory particles that bind at the outer surfaces of the protea-
some  rings. The 19S regulatory particle is the proteasome
regulator that recruits fully folded ubiquitinated protein
substrates for degradation and proceeds with their ATP-
dependent unfolding and translocation towards the proteo-
lytic sites of the 20S proteasome.
The proteasome is a well established target for therapeutic
drug development (Kisselev et al., 2012), including the treat-
ment of cancer (Manasanch & Orlowski, 2017). Bortezomib
was the first proteasome inhibitor to be approved for clinical
use against multiple myeloma. Subsequently, two second-
generation inhibitors have been approved for the treatment of
relapsed or refractory multiple myeloma, namely carfilzomib
(Moreau et al., 2012) and, more recently, ixazomib (Muz et al.,
2016), the first orally administered proteasome inhibitor.
Next-generation proteasome inhibitors are being developed
for higher efficacy and for the treatment of a wider range of
medical conditions. These include compounds aimed at
selectively targeting proteasome subtypes, namely constitutive
proteasomes or immunoproteasomes, with minimum cross-
reactivity in order to minimize off-target toxicity (Huber &
Groll, 2012; Huber et al., 2016; Xin et al., 2016). The devel-
opment of drugs that specifically target the immunoprotea-
some further extends the therapeutic potential of proteasome
inhibitors, including to the treatment of inflammatory dis-
orders (Basler et al., 2015). Below, we discuss the potential of
targeting the proteasome against malaria, and the likely
extension of this approach to other protozoan infections.
Drug discovery is often guided by the knowledge of the
structure of a protein target and of its interactions, at the
atomic level, with candidate or prototype ligands. The first
crystal structure of a 20S proteasome was obtained for a
simpler archaeal complex (Lowe et al., 1995). Subsequently,
eukaryotic 20S proteasome crystal structures were determined
for yeast (Groll et al., 1997), constitutive bovine and human
complexes (Unno et al., 2002; Harshbarger et al., 2015), and
the constitutive proteasomes and immunoproteasomes
from mouse (Huber et al., 2012). Over the years, X-ray
crystallography has been pivotal in providing structural
information for the development of proteasome inhibitors as
therapeutic agents (Groll & Huber, 2004; Borissenko & Groll,
2007). However, the field of biological structural electron
microscopy has recently seen an enormous transformation
(Kuhlbrandt, 2014; Vinothkumar & Henderson, 2016), and
high-resolution protein structures can now be obtained using
electron cryomicroscopy (cryo-EM) and single-particle
analysis. We have explored their applicability to study
protein–ligand interactions using first the human 20S protea-
some core, providing a proof of principle for the potential use
of these methods in structure-based drug discovery and
development (da Fonseca & Morris, 2015). Subsequently, a
similar approach was used to provide the structural informa-
tion needed to validate the Plasmodium falciparum protea-
some as a viable molecular target against malaria and also to
guide the improvement of the prototype specific Plasmodium
proteasome inhibitors tested as potential antimalarials (Li,
O’Donoghue et al., 2016; Li, Bogyo et al., 2016). Within the
context of the proceedings of the Second CCP-EM Spring
Symposium, here we review our cryo-EM analysis of ligand-
bound human and P. falciparum proteasomes, focusing on a
detailed description of the methods we used for structure
determination, including our strategy to avoid orientation bias
of the proteasome on electron-microscope grids and the icr3d
program used for three-dimensional reconstruction.
2. Cryo-EM of eukaryotic 20S proteasomes
The behaviour of 20S proteasomes from higher eukaryotes
on electron-microscope grids diverges from that of archaeal
proteasomes, which have been used as reliable test samples in
the development of cryo-EM and image-processing methods.
In this context, structures of archaeal 20S proteasomes have
been determined by cryo-EM and single-particle analysis at
resolutions of 2.8 A˚ (Campbell et al., 2015; Grant & Grigorieff,
2015) and 2.4 A˚ (Danev et al., 2017), the latter by the analysis
of images recorded using a phase plate. Such cryo-EM studies
take advantage of the high stability and homogeneity of the
archaeal complex at high concentrations and under buffer
conditions that are highly suitable for the preparation of cryo-
EM grids. Furthermore, the lower complexity of the archaeal
proteasome, which is formed by homo-heptameric rings of
 and  subunits, results in a higher order D7 symmetry
assembly. This allows a sevenfold increase in internal aver-
aging of the archaeal proteasome subunits compared with that
in the C2 symmetrical eukaryotic complexes, which greatly
facilitates image processing. The cryo-EM analysis of the
archaeal 20S proteasome can in principle be performed with a
significantly smaller stack of molecular images than is required
for the analysis of eukaryotic complexes, making the analysis
significantly less computationally demanding. Furthermore,
the pseudo-symmetry of the eukaryotic 20S proteasome can
lead to image misalignments that are out of register around
the pseudo-sevenfold axis, which do not occur with the exact
sevenfold symmetry of the archaeal  and  subunit rings. On
the other hand, the structural analysis of archaeal complexes
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cannot provide information on the ligand specificity and
selectivity of each of the three distinct proteolytic sites of
eukaryotic 20S proteasomes. The selectivity of each of the
three distinct proteolytic active sites of the eukaryotic
complex, associated with subunits 1, 2 and 5, is dictated by
the different amino-acid side chains lining each of the ligand-
binding pockets, which differ from those lining the single
archaeal active site. Therefore, detailed structural information
on each of the eukaryotic active sites is essential to assist drug
development.
2.1. Preparation of cryo-EM grids of 20S proteasome samples
from higher eukaryotes
Samples of the human and P. falciparum 20S proteasome
cores were incubated in solution for 1 h at 37C in the
presence of a concentration of ligand optimal for maximal
binding while still preserving active-site specificity, as deter-
mined by in vitro binding assays under similar conditions (da
Fonseca & Morris, 2015; Li, O’Donoghue et al., 2016). After
incubation, the samples were loaded onto electron-microscope
grids. We used Quantifoil 1.2/1.3 grids freshly coated with a
thin layer of carbon. For the preparation of these grids, thin
carbon films were prepared by carbon evaporation onto
freshly cleaved mica using an Edwards Auto 306 coating unit.
The Quantifoil grids were quickly dipped in acetone for 2–3 s
in order to improve their wettability, and immediately placed
on filter paper submerged in ultrafiltered water within a Petri
dish. The carbon film was floated from the mica surface and
the filter paper was raised so that the carbon film was
harvested on the surfaces of the grids. After the grids had been
rendered hydrophilic by glow discharge, 2 ml of 20S protea-
some sample was applied onto the thin carbon for approxi-
mately 20 s, the excess solution was removed by blotting and
the grids were flash-frozen into vitreous ice using an FEI
Vitrobot.
In the case of the human 20S proteasome, glow discharge of
the electron-microscope grids in a partial vacuum of atmo-
spheric air, at 20 Pa for 20 s, using an Emitech K950X led
to a strongly preferred top-view orientation of the complexes.
Under these conditions, the outer surface of the proteasome
-rings preferentially interacts with the carbon film (Fig. 1a), a
behaviour that has previously been observed for other
eukaryotic 20S proteasome samples (Baumeister et al., 1988;
Tanaka et al., 1988). Since data sets with this orientation bias
are not suitable for three-dimensional analysis, we investi-
gated modifying the glow-discharge protocol. We found that
glow discharge of the grids in the presence of pentylamine
(also known as amylamine), at a pressure of 50 Pa for 20 s,
resulted in a radical reorientation of the human proteasome,
with >90% of the molecular images corresponding to side
views perpendicular to the long axis of the proteasome
(Fig. 1b). Since these side views have a complete and even
distribution 360 around the proteasome central axis, they are
well suited for an accurate and isotropic three-dimensional
reconstruction (da Fonseca & Morris, 2015). In order to render
the carbon surface of the electron-microscope grids hydro-
philic and suitable for an adequate orientation of the human
proteasome, pentylamine was introduced into the glow-
discharge chamber either as 3  50 ml drops on a piece of filter
paper or as 50 ml in a small open vial. Interestingly, the 20S
proteasome from P. falciparum showed a different behaviour
and yielded a reasonable mixture of top and side views on
carbon films glow-discharged in atmospheric air (Li,
O’Donoghue et al., 2016), appearing to be closer to that
observed for archaeal proteasomes. Since pentylamine treat-
ment did not seem to affect this distribution, it was not used in
the glow discharge of grids prepared for structural analysis of
the Plasmodium complex.
Glow discharge in the presence of pentylamine has
previously been observed to modify the adhesion of macro-
molecules to carbon films by creating a
positively charged surface, in contrast to
the negative charge obtained by glow
discharge in atmospheric air (Dubochet
et al., 1971; Aebi & Pollard, 1987). We
were able to replicate this change in
the orientation of the human 20S
proteasome in a number of different
glow-discharge units. However, in all
cases we observed that significant care
was required to maintain the positive
charge on the carbon during glow
discharge. If the glow discharge was
either prolonged significantly beyond
20 s or the vacuum was allowed to
increase significantly, the pentylamine
effect was reversed and the grids
appeared to become negatively charged,
with the predominance of top views of
the human 20S proteasome returning.
This is related to the colour of the
glow discharge: in the presence of
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Figure 1
EM images of negatively stained fields of 20S proteasome complexes showing the effect of altering
the surface charge of the carbon support film on the orientation of the human 20S proteasome. (a)
Glow discharge of the EM grid in a partial vacuum of atmospheric air results in a strongly biased
proteasome orientation with predominant top views. (b) Glow discharge in a partial vacuum
containing pentylamine vapour results in a predominance of side views.
pentylamine the glow has a characteristic pure blue colour,
whereas in air it is violet (Aebi & Pollard, 1987), and loss of
the required positive charge can be monitored by a transition
of the colour of the glow from the desired blue to violet. We
also observed that the 20S proteasome from Saccharomyces
cerevisiae shows the same orientation changes with different
carbon charges as the human complex. For a more general
application in cryo-EM, the sensitivity of the orientation of
human and yeast 20S proteasomes to the polarity of the
charge at the carbon surface, their ready availability from
commercial sources and the ease with which proteasome top
and side views can be distinguished make them a useful
control for evaluating the effectiveness of glow-discharge
procedures of carbon films in the presence of pentylamine.
When preparing batches of glow-discharged grids to image
other proteins or protein complexes, any particle reorientation
may not be as obvious as for the proteasome. Because the
charge of the carbon can be easily reversed during glow
discharge in the presence of pentylamine, a simple way to
evaluate it is to load a single grid from a batch of treated grids
with human or yeast 20S proteasomes, which can be negatively
stained and readily imaged by electron microscopy at room
temperature. The orientation of the proteasomes in such a grid
provides a control for the efficiency of the pentylamine
treatment for all of the grids in the batch glow-discharged at
the same time. When the pentylamine effect is successfully
achieved, the positive charges at the carbon surfaces are stable
for a few hours.
2.2. High-resolution cryo-EM data collection
We have described our strategy to collect high-resolution
cryo-EM images of both ligand-bound human and P. falci-
parum 20S proteasome samples (da Fonseca & Morris, 2015;
Li, O’Donoghue et al., 2016). Briefly, 20S proteasome mole-
cular images were recorded using an FEI Titan Krios electron
microscope with a Falcon II direct electron detector. In both
cases images were captured as 17 individual frames during a
1 s exposure at a calibrated sampling of 1.04 A˚ pixel1. All
recorded images were inspected for their signal-to-noise ratio
and the recovery of isotropic high-resolution information to
at least about 4 A˚, as evaluated by the recovery of contrast-
transfer function modulation in the image power spectra. For
the images selected for further analysis the sum of all frames,
corresponding to an accumulated dose of about 50 e A˚2,
was used for particle picking, taking advantage of the higher
signal-to-noise ratio that facilitates the unambiguous identifi-
cation of molecular images. The subsequent image-processing
and three-dimensional refinement procedures were performed
using the sum of frames 3–10 of each selected image. The first
recorded frames were excluded since beam-induced particle
movements are significantly accentuated in the early stages of
the exposure, limiting the recording of high-resolution infor-
mation (Vinothkumar et al., 2014). The last frames were
excluded in order to limit the accumulated exposure to less
than 30 e A˚2 and therefore to reduce the loss of high-
resolution information owing to radiation damage. The strin-
gent selection of images for processing, based on the recovery
of isotropic high-resolution information in their power spectra
as described above, and the fact that for each of those images
the selected frames were effectively acquired within 0.45 s,
with negligible effects owing to microscope-stage drift, led us
to judge that alignment of the frames recorded for each
exposure was not required. For both the human and the
P. falciparum 20S proteasome samples, all images were
recorded from a single cryo-EM grid during a single data-
collection session.
3. Image-processing strategy
The single-particle analysis refinement routines used in the
processing of the data sets for both the human and the
P. falciparum 20S proteasomes have been described, together
with the strategy for protein model building (da Fonseca &
Morris, 2015; Li, O’Donoghue et al., 2016). Briefly, the single-
particle analysis refinement routines consisted of rounds of
image alignment and angular assignment by projection
matching using the AP SH program from the Spider software
package (Frank et al., 1996), and three-dimensional recon-
struction and three-dimensional forward projections using the
locally developed programs icr3d (Institute of Cancer
Research 3D reconstruction) and icr3dpro (Institute of
Cancer Research 3D projections), respectively. The programs
icr3d and icr3dpro are described in detail below. In the
analysis of both the human and the P. falciparum 20S
proteasomes, a crucial step was the use of an appropriate
initial reference. For this purpose, we originally used a model
map, low-pass filtered to 20 A˚, calculated from coordinates
fitted into the 20S core region of a cryo-EM map of the human
26S proteasome (da Fonseca et al., 2012). This filtered model
map was found to retain sufficient detail to still allow differ-
entiation between the closely related seven  and seven 
subunits, which is required to avoid incorrect alignment to
reference projections related by pseudo-sevenfold symmetry,
while at the same time avoiding model bias. Initially, this
reference was used as the starting model for the analysis of the
human 20S proteasome core in the apo state (unpublished
data). The resulting map, low-pass filtered to 20 A˚, was used as
the starting reference for the analysis of a ligand-bound
human proteasome (da Fonseca & Morris, 2015), which in turn
was used as the starting reference for the analysis of the
P. falciparum complex (Li, O’Donoghue et al., 2016).
3.1. The icr3d and icr3dpro programs
3.1.1. Geometrical weighting. For our analysis of both the
human and P. falciparum 20S proteasomes, three-dimensional
maps were calculated using a locally developed program,
icr3d, while a second closely related program, icr3dpro, was
used to generate two-dimensional reprojections from these
three-dimensional maps, which were used for refinement of
the alignment and angular assignment parameters of the data.
In single-particle analysis, three-dimensional reconstructions
from projection images are commonly calculated by
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either real-space or Fourier-space methods (Grigorieff, 2007).
Real-space reconstructions typically involve weighted back-
projection algorithms. Here, individual two-dimensional
images are back-projected into a three-dimensional volume in
directions corresponding to their projection directions (char-
acterized by Euler angles), which have previously been
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Figure 2
Scheme for the Fourier-space reconstruction used in the program icr3d. (a) Three-dimensional reconstruction in Fourier space by the summation of
central sections (two are shown, one in blue and one in red), which derive from the projection angles of the two-dimensional images (indicated by red
and blue arrows). The depth of each central section depends on the reciprocal dimension of the reconstructed object (1/D) measured in the projection
direction. (b) Contributions from the input Fourier components of two individual particle images (red and blue points) to the output Fourier components
of the three-dimensional reconstruction (black points) are confined to the central section (red and blue dashed lines) as in (a). These are added to
neighbouring three-dimensional Fourier components within ellipsoidal contributing envelopes (red and blue ellipses), the dimensions of which are
reciprocally related to the maximum dimensions of the reconstructed object in the relevant directions. (c) Maximum dimensions of a reconstructed
object expressed as fractions of the cubic reconstructed volume shown in the xy and xz planes. (d) Corresponding ellipsoidal Fourier-space contribution
envelopes (red ellipses), which can be compared with the spherical contribution envelopes (black circles) that relate to a reconstructed object with
maximum dimensions equal to the cubic reconstructed volume. (e) The fractional distance (dFrac) used to determine sinc-weighted contributions to the
output Fourier components is calculated from the distances (B and B0) between the input Fourier components (red dots) and the output Fourier
components (black dots) as a fraction of the distance to the edge of the ellipsoidal contributing envelope (A and A0).
estimated by projection matching or angular reconstitution.
The reconstructed volume is the sum of these back-projected
contributions. Consequently, it is necessary to use a weighting
procedure to compensate for the unequal contributions at
different spatial resolutions resulting from this approach.
The exact-filter three-dimensional reconstruction algorithm
(Harauz & van Heel, 1986) performs this function, as well as
taking into account the uneven angular distributions in the
input data that are often encountered in cryo-EM experi-
ments. The exact filter exploits the equivalence between two-
dimensional projections of a three-dimensional object and
central sections of its three-dimensional Fourier transform.
These central sections have a depth that is reciprocally related
to the dimension of the reconstructed object in the projection
direction. The finite depth of the central sections leads to
Fourier contributions from different images overlapping
(Fig. 2a), and the extent of overlap can be used to obtain
Fourier-space weighting functions, which serve to attenuate
such regions of multiple overlapping contributions. The
weighting functions are used to filter Fourier transforms of the
input images, which are then back-transformed into real space
and back-projected to give the three-dimensional recon-
struction.
In the icr3d program an equivalent weighting approach to
that of Harauz & van Heel (1986) has been implemented, but
in this case the input image data are merged in Fourier space.
Fourier transforms of the input data are subjected to coordi-
nate transformation defined by their assigned Euler angles to
create central sections through the three-dimensional Fourier
transform of the reconstructed volume. At this stage, the
rotational and translational parameters obtained during the
alignment of the individual molecular images against the
current reference structure can be applied to original un-
interpolated images by phase-shifting the Fourier components,
thereby minimizing the number of interpolations in deriving
the three-dimensional structure. Contributions from each
Fourier component of the input images are added to those
Fourier coefficients of the output three-dimensional Fourier
transform that fall within a contribution envelope (Fig. 2b).
The dimensions of the contribution envelope are calculated
in a similar way to the depths of the Fourier-space central
sections in the exact-filter back-projection approach, i.e 1/D
(Figs. 2a and 2b), where D is the linear dimension of the object
(van Heel & Harauz, 1986). Given that the generalized object
may have different linear dimensions along each of its major
axes (Fig. 2c), the Fourier-space contribution envelope exists
as an ellipsoid and the dimensions of its axes correspond to
half the reciprocal dimension of a bounding cuboid containing
the reconstructed object (Figs. 2c and 2d). Each Fourier
component of the input image will contribute to the Fourier
components of the reconstructed object that lie within its
contribution envelope (Figs. 2b and 2e), and each Fourier
component of the reconstructed object is calculated as a
weighted average of all of its contributing input image Fourier
components. Individual contributing Fourier components are
weighted by a geometrical weighting factor (Wgeom) evaluated
as a sinc function of the fractional distance between the input
Fourier component and the output Fourier component to
which it is contributing, dFrac (Fig. 2e),
Wgeom ¼ ð; dFracÞ: ð1Þ
The resulting output three-dimensional Fourier compo-
nents correspond to the geometrically weighted average of
input Fourier components using a Wiener filter to avoid
excessive noise being introduced into Fourier components
where there are a small number of contributions from the








The weighting approach adopted here is similar to that used
in the three-dimensional analysis of two-dimensional crystals,
where sinc functions are fitted along reciprocal-lattice lines
through irregularly distributed sets of Fourier components
from tilted images to provide the Fourier components of a
regular grid required for three-dimensional Fourier synthesis
(Amos et al., 1982). This provides an effective means of
interpolation between the non-integral sample points arising
from the two-dimensional input data and the output integral
three-dimensional grid. Furthermore, by setting the contri-
bution envelope to match the dimensions of the reconstructed
object, more averaging can be achieved, potentially improving
the signal-to-noise ratio. This geometrical weighting approach
is the major novel feature of icr3d.
Finally, in icr3d the Fourier transforms of both the input
images and the three-dimensional reconstruction can be
subsampled, in order to increase the reconstruction accuracy,
by padding the real-space input images in boxes n times the
original dimensions. Typical values for n are 2 or 3, depending
on the image box size. Both our human and P. falciparum 20S
proteasome cryo-EM maps were calculated using a padding
factor of 3.
3.1.2. The contrast-transfer function. In icr3d, the contrast-
transfer function (CTF) correction is achieved in two steps.
Firstly, correction of the phases is carried out by phase reversal
in the appropriate frequency zones in the Fourier transforms
of complete microscope images prior to particle selection,
thereby maximizing the recovery of information from indivi-
dual images delocalized by the point-spread function into
neighbouring regions. In our analysis of the 20S proteasome,
this was performed with the Tigris program flipctf using the
defocus values calculated using the Tigris program findctf.
Conversely, correction for the amplitude oscillations arising
from the CTF is more effectively achieved at the stage of the
weighted merging of the Fourier components from individual
molecular images into the reconstructed three-dimensional
Fourier transform. This avoids boosting the noise in the
frequency zones where the CTF is close to zero. Additional
weighting terms for the input images are included in icr3d to
take account of a defocus-dependent envelope value (Wdef)
for each Fourier component, together with the correlation
coefficient for the whole input image. In each case, these terms
serve to upweight Fourier components where the signal-to-
noise ratio is higher. Combined, this gives rise to a global
weighting function (Wglobal),
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Wglobal ¼ Wgeom WCTF Wdef Wcc: ð3Þ






= f þPWglobal WCTF
 
: ð4Þ
The parameters used for the defocus envelope weighting
function result in the sharpening of the reconstruction, and
therefore optimal sharpening of the resulting map can be
achieved by applying relatively small values of negative B
factor. For the interpretation of both the human and the
P. falciparum cryo-EM maps, a B factor of 50 A˚2 was used to
aid in model building (da Fonseca & Morris, 2015; Li,
O’Donoghue et al., 2016).
3.1.3. The icr3d program and its input parameters. Once all
of the input data have been merged in Fourier space, as
described above, three-dimensional reconstructions in real
space are obtained by Fourier transformation. With an
adequate choice of input parameters, the resulting recon-
structions obtained using icr3d are characterized by a high
signal-to-noise ratio, with unambiguous protein densities that
are clearly distinguishable from the background, while
retaining the recovery of high-resolution details (Fig. 3), as
observed in our maps of the human and the Plasmodium 20S
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Figure 3
Effect of the different parameters used in icr3d reconstructions. (a–e) Tests with the model density illustrated in Fig. 2(c). (a) Sections of model density.
(b, c, d) Sections from reconstructed density produced from input projection images sampled at 30 intervals. (b) Sections from reconstruction with the
contribution envelope set to match the dimensions of the reconstructed object as illustrated in Fig. 2(c) (i.e. the standard mode of usage for icr3d). (c)
Sections from reconstruction with the contribution envelope set to match the dimensions of the reconstructed volume. (d) Sections from reconstruction
calculated with the contribution envelope set to match the dimensions of a reconstructed volume of twice the size used in (c). (e) Distribution of Euler
angles of the input projection images with 30 sampling, used to calculate the maps in (b–d). ( f ) Reconstruction of the human 20S proteasome from cryo-
EM data (da Fonseca & Morris, 2015) illustrating the effect of different parameters on a single section of reconstructed density. (i) Reconstruction using
CTF weighting, CTF amplitude correction and set to match the dimensions of the 20S proteasome; (ii) magnified region of image (i); (iii) as (ii) but with
the contribution envelope set to match the reconstructed volume; (iv) as (ii) but with no CTF amplitude correction; (v) as (iv) but with no CTF weighting.
proteasomes (da Fonseca & Morris, 2015; Li, O’Donoghue et
al., 2016).
Figs. 3(a)–3(e) illustrate the effects of geometrical weighting
and varying the contribution envelope of each input Fourier
component on three-dimensional reconstructions. These were
calculated using a test data set obtained by forward-projecting
the model map shown in Fig. 2(c), which is characterized by an
axial ratio of 2.3, using a sparse set of projection images. Using
icrd3d with the contribution envelope set to match the linear
dimensions of the reconstructed object results in good
recovery of the internal detail of the reconstruction (Fig. 3b)
compared with the original model map (Fig. 3a). The back-
ground is quite clean, although with some residual modulation
arising from the deliberate use of projection images with Euler
angles with 30 spacing (Fig. 3e). Conversely, significant
internal detail is lost coupled to the exaggeration of low
frequencies and increased background noise if the contribu-
tion envelope is set to match the dimensions of the recon-
structed volume (Fig. 3c). These effects are further
exaggerated if the contribution envelope dimensions are set
to match a reconstructed volume which is doubled in size
(Fig. 3d). This overrepresentation of low-frequency informa-
tion has previously been observed with the related exact-filter
back-projection approach applied to filamentous systems
which have inherently high axial ratios (Paul et al., 2004). The
effect of the additional weighting parameters can be assessed
with experimental cryo-EM images of the human 20S
proteasome (da Fonseca & Morris, 2015; Fig. 3f). Here, the
reconstruction calculated with optimized weighting factors
(Fig. 3f, i and ii) is compared with reconstructions with no
allowance for the dimensions of the reconstructed object
(Fig. 3f, iii), without CTF amplitude correction (Fig. 3f, iv) and
without CTF weighting (Fig. 3f, v). In each case the signal-to-
noise ratio is reduced, with an additional attenuation of high
frequencies when the reconstructions are calculated using no
amplitude correction or CTF weighting (Fig. 3f, iv and v).
The programs icr3d and icr3dpro are written in C++ as part
of the Tigris package. icr3d reads input images and their Euler
angles in IMAGIC format (van Heel et al., 1996) and outputs a
three-dimensional reconstruction also in IMAGIC format.
icr3dpro takes a three-dimensional density map and a list of
Euler angles and returns a set of two-dimensional projections
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Figure 4
Cryo-EM structure of the human 20S proteasome with an inhibitor bound, showing the map and coordinates deposited in the Electron Microscopy Data
Bank and Protein Data Bank with accession codes EMD-2981 and 5a0q, respectively (da Fonseca & Morris, 2015). (a) Overall view of the density map
(mesh) and protein coordinates (cartoon). (b) The map shown in (a) cut to reveal the location in the proteasome inner cavity of the Thr1 residues (shown
as spheres) at the active sites of subunits 1, 2 and 5. (c) Close-up views of the three active sites, showing the map densities (mesh representation)
colour-coded according to the local resolution estimated with ResMap (Kucukelbir et al., 2014) with protein coordinates represented as a cartoon.
Densities for the ligand (encircled by dashed lines) are clearly seen extending from the Thr1 residues of subunits 1, 2 and 5 (indicated by arrows). (d)
Close-up view of the cryo-EM map (mesh representation) and model coordinates (shown as sticks) for the 5 subunit of the human 20S proteasome, with
the L3VS moiety of the inhibitor (coloured yellow) extending from the Thr1 residue (indicated by an arrow). The ligand LLL tripeptide mimics
proteasome substrate positions P1–P3, as labelled, where the side chains at positions P1 and P3 are oriented towards the ligand-binding pocket, while
that at position P2 is oriented towards the inner cavity of the proteasome. (a), (b) and (c) were created using UCSF Chimera (Pettersen et al., 2004) and
(d) was created using PyMOL (Schro¨dinger).
using the geometrical weighting approach. Both programs are
implemented in the Tigris software package, which is publicly
available at https://sourceforge.net/projects/tigris/.
4. The cryo-EM structure of a ligand-bound human 20S
proteasome: a proof of principle
X-ray crystallography has been extensively used to study the
structural details of the interaction of eukaryotic 20S protea-
somes with inhibitory ligands, particularly using complexes
purified from S cerevisiae, in order to guide drug discovery.
Building on this, we investigated the suitability of using cryo-
EM for such studies, taking advantage of the recent advances
in the field, using human 20S proteasomes with a ligand bound
(da Fonseca & Morris, 2015). The chosen ligand was
adamantaneacetyl-(6-aminohexanoyl)3-(leucyl)3-vinylmethyl-
sulfone (AdaAhx3L3VS), a highly potent proteasome inhi-
bitor that covalently binds to the Thr1 residue of the
proteolytically active subunits of the 20S proteasome (Bogyo
et al., 1997; Kessler et al., 2001). In our cryo-EM map (Figs. 4a
and 4b), the protein backbone of each individual proteasome
subunit is clearly identified and densities are resolved for most
of the proteasome side chains, consistent with the estimated
resolution of about 3.5 A˚. Furthermore, extra densities
extending from the proteolytically active Thr1 residues of the
1, 2 and 5 subunits (Fig. 4b) can be directly assigned to the
L3VS moiety of the ligand AdaAhx3L3VS (Figs. 4c and 4d). No
densities were recovered for the AdaAhx3 moiety of the
ligand at any of the three proteasome active sites, which is
consistent with a flexible conformation of this part of the
ligand within the proteasome inner cavity.
In the cryo-EM map of the human 20S–AdaAhx3L3VS
complex (da Fonseca & Morris, 2015), the L3VS moiety is
particularly well resolved in the 5 active site, clearly showing
its extended near-planar conformation and allowing molecular
building of the vinyl-sulfone group and the three leucine side
chains (Figs. 4c and 4d). The densities for the L3VS moiety of
the ligand at the 2 and 1 active sites are weaker than those
extending from the 5 Thr1 (Fig. 4c), which can be attributed
to lower ligand occupancy at these active sites. This is
consistent with the results obtained from in vitro assays of the
inhibition of mammalian proteasomes by AdaAhx3L3VS,
which show higher potency of the ligand towards the 5 active
site than to those in the 1 and 2 subunits (Kessler et al.,
2001). The consistency of proteasome active-site occupancy
observed in our cryo-EM map and the ligand potency towards
the different proteasome active sites is a consequence of the
use of similar close-to-physiological conditions, and illustrates
one of the main advantages of using cryo-EM in the study of
protein–ligand interactions in general (da Fonseca & Morris,
2015). The preservation of such optimal ligand-binding
conditions is commonly compromised when studying protein–
ligand interactions by X-ray crystallography, which has been
the method of choice for the study of eukaryotic 20S protea-
somes. In these studies, pre-formed protein crystals are soaked
in solutions containing high ligand concentrations, under
conditions that primarily must preserve the integrity of the
protein crystals rather than mimicking those for physiological
protein–ligand interactions. Under such conditions ligand
selectivity can be difficult to be preserve, particularly when
comparing closely related ligands and/or when targeting
closely related active sites.
Apart from allowing the structural study of protein–ligand
interactions under conditions that are closer to physiological,
cryo-EM also has the important advantage of requiring
significantly lower amounts of protein than other methods of
structure determination. This extends the feasibility of high-
resolution structural analysis to protein samples that, for
biochemical reasons, are difficult to prepare in high quantities.
An example is the 20S proteasome from P. falciparum, our
cryo-EM structure of which is now being explored in the fight
against malaria (Li, O’Donoghue et al., 2016; Li, Bogyo et al.,
2016), as outlined below.
5. The cryo-EM structure of the P. falciparum
proteasome in the discovery of new antimalarials
P. falciparum is the parasite that is responsible for the most
severe form of malaria. This mosquito-transmitted disease
affects hundreds of millions of people every year, particularly
in tropical and subtropical climates. According to the World
Health Organization, the vast majority of the hundreds of
thousands of people killed by malaria in 2015 were young
children under the age of five (World Health Organization,
2015). Artemisinin derivatives are now the front-line anti-
malarials, and while the number of people affected by malaria
is still staggering, the use of artemisin-based combination
therapies has contributed to a recent significant reduction in
the world malaria burden. However, resistance of P. falci-
parum to artemisinin derivatives has emerged in Southeast
Asia (Ashley et al., 2014; Tilley et al., 2016), and its spread
represents a serious threat to human health and to the current
efforts towards the global control and eventual eradication of
malaria, urging the development of new efficient antimalarials.
Inhibition of the Plasmodium proteasome is toxic to the
parasite at all stages of its life cycle (Gantt et al., 1998), and it
has been suggested that the Plasmodium proteasome can be
specifically targeted (Li et al., 2012; Li, Tsu et al., 2014; Li, van
der Linden et al., 2014). These studies indicate a potential role
of parasite proteasome inhibition in the development of
next-generation antimalarials. However, the development of
proteasome inhibitors as antimalarials requires knowledge, at
the molecular level, of the differences between the parasite
and human proteasome ligand-binding preferences, in order to
guide the development of highly specific drugs with thera-
peutic potential.
High-resolution structural information is required in order
to fully understand the molecular basis of ligand specificity
and in order to serve as a framework for the development of
specific drugs with therapeutic potential. While X-ray crys-
tallography has been the method of choice for the structural
analysis of 20S proteasome–ligand interactions, the low yield
of 20S proteasome samples obtained from P. falciparum
cultures makes its crystallization impractical. On the other
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hand, the preparation of cryo-EM grids requires a significantly
lower amount of protein than crystallization. A cryo-EM grid
can be prepared using as little as 2 ml of sample at a protein
concentration of about 0.1 mg ml1, when using electron-
microscope grids coated with a continuous thin layer of
carbon, although batches of grids must be prepared for the
optimization of freezing conditions and cryo-EM data collec-
tion. Hence, we built on our previous experience with the
cryo-EM analysis of the human 20S proteasome with a ligand
bound (da Fonseca & Morris, 2015) in order to determine the
structure of the P. falciparum proteasome (Li, O’Donoghue et
al., 2016).
The high-resolution cryo-EM structure of the P. falciparum
20S proteasome (Fig. 5) was determined with the complex
bound to a new prototype specific inhibitor, WLW-vs, that was
identified by extensive biochemical and functional assays (Li,
O’Donoghue et al., 2016). This compound is a peptide-vinyl
sulfone that, like other standard proteasome inhibitors,
comprises a tripeptide moiety (WLW) that mimics the
proteasome substrate positions P1–P3, counted upstream from
the proteolytic scissile bond. The side chains of these three
amino-acid residues confer specificity towards the different
proteasome proteolytic sites. Functional assays revealed that
this compound is unusual in its binding preference towards the
2 subunit of the Plasmodium proteasome, while avoiding
binding to the parasite proteasome 1 and 5 active sites and
all of those in the human complex (Li, O’Donoghue et al.,
2016). This specificity is confirmed by our cryo-EM structure
of the Plasmodium 20S–WLW-vs complex at a resolution of
about 3.6 A˚, where the ligand is found only at the Plasmodium
2 binding pocket (Fig. 5b). Our structure clearly shows that
the molecular basis for this unusual selectivity arises from the
unpredictably spacious Plasmodium 2 binding pocket, which
permits accommodation of the ligand tryptophan side chains
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Figure 5
Cryo-EM structure of the P. falciparum 20S proteasome with an inhibitor bound, showing the map and coordinates deposited in the Electron Microscopy
Data Bank and Protein Data Bank with accession codes EMD-3231 and 5fmg, respectively (Li, O’Donoghue et al., 2016). (a) Overall view of the density
map (mesh) and protein coordinates (cartoon). (b) Close-up view of the density map (mesh) and model coordinates (sticks) showing the WLW-vs
inhibitor (teal) bound to Thr1 of the 2 subunit. The ligand WLW tripeptide mimics proteasome substrate positions P1–P3, as labelled. As for other
tripeptide proteasome inhibitors, the side chains at positions P1 and P3 are oriented towards the ligand-binding pocket, while that at position P2 is
oriented towards the inner cavity of the proteasome. (c) Model of the P. falciparum 2 active site with bound ligand, as determined by cryo-EM, viewed
towards the inner cavity of the proteasome. (d) P. falciparum 1 active site with superimposed inhibitor coordinates, showing that the tryptophan side
chains of the ligand, at positions P1 and P3, cannot be accommodated at this active site owing to steric constraints. (e) P. falciparum 5 active site with
superimposed inhibitor coordinates, showing that the tryptophan side chain of the ligand at position P1 cannot be accommodated in this active site owing
to steric constraints. In (c), (d) and (e) the protein model is represented as van der Waals surfaces and the ligand as sticks. (a), (c), (d) and (e) were
created using UCSF Chimera (Pettersen et al., 2004) and (b) was created using PyMOL (Schro¨dinger).
(Fig. 5c), while binding to the Plasmodium 1 and 5 pockets
is shown to be impaired by steric constraints (Figs. 5d and 5e).
Steric constraints also impair the binding of WLW-vs to all of
the human proteasome active sites, thus explaining the
specificity of this compound towards the parasite complex, as
was shown previously (Li, O’Donoghue et al., 2016). Most
importantly, our structure provides a suitable framework to
assist the drug development currently in progress for the
improvement of Plasmodium proteasome specific inhibitors
into potential antimalarials for clinical use (Li, Bogyo et al.,
2016).
6. Future prospects
Here, we have described in detail the methods that we have
used to determine the cryo-EM structures of ligand-bound
human and P. falciparum 20S proteasomes, namely the
strategy to avoid orientation bias of the human proteasome on
cryo-EM grids and our approaches for data collection and
image analysis, with emphasis on the details of the icr3d three-
dimensional reconstitution algorithm. Our studies demon-
strate the feasibility and advantages of using cryo-EM and
single-particle analysis to derive the structures of ligand-
bound protein complexes relevant to guide the design and
improvement of effective drugs for clinical use (da Fonseca &
Morris, 2015; Li, O’Donoghue et al., 2016; Li, Bogyo et al.,
2016). These studies have established and exploited the ability
of cryo-EM to allow work under near-physiological solution
conditions and inhibitor concentrations similar to those used
for in vitro ligand-binding assays, which are usually not
attainable using other methods of protein structure determi-
nation. Consequently, cryo-EM permits the structural analysis
of protein–ligand complexes where binding selectivity is
preserved, and where ligand occupancy is found to be
consistent with the results of in vitro binding assays. This is of
particular relevance when investigating the structural basis for
ligand selectivity between chemically related ligands and/or
active sites. In the eukaryotic proteasome, the substrate
selectivity of the three related but distinct active sites asso-
ciated with the 1, 2 and 5 subunits is dictated by constraints
resulting from the different amino-acid side chains lining each
of the three substrate-binding pockets (Fig. 5). The existence
of three closely related proteolytic active sites with distinct
substrate preferences within the eukaryotic 20S proteasome
makes it a particularly interesting system to investigate by
cryo-EM, with the potential to provide information suitable to
understand the structural basis for their selectivity.
Our work shows that cryo-EM can be used to resolve not
only ligand selectivity between the three distinct proteasome
active sites, as illustrated in Fig. 5, but also ligand-binding
specificity between the human and Plasmodium complexes, as
we have previously reported (da Fonseca & Morris, 2015; Li,
O’Donoghue et al., 2016). This type of approach can in prin-
ciple be extended to the study and optimization of the selec-
tive inhibition of different classes of human proteasomes
(constitutive proteasomes, immunoproteasomes or thymo-
proteasomes) for potential therapeutic usage. Furthermore,
we showed that although they are closely related there are
differences between the human and P. falciparum 20S
proteasome active sites that allow specific targeting in the
development of potential new antimalarials, and it is likely
that the same applies to other disease-causing protozoan
parasites. As for the analysis of the P. falciparum proteasome,
here cryo-EM structures may be valuable owing to both the
requirement for smaller amounts of protein and the preser-
vation of ligand selectivity (Li, Bogyo et al., 2016; Bibo-
Verdugo et al., 2017). In this context, a new compound was
recently identified that selectively targets 20S proteasomes
from pathogenic kinetoplastid parasites, namely Trypanosoma
cruzi, T. brucei spp. and Leishmania spp., which cause Chagas
disease, sleeping sickness and leishmaniasis, respectively
(Khare et al., 2016). This new compound does not inhibit
mammalian proteasomes and acts by a noncompetitive
mechanism, although a direct structural analysis is still
required to fully characterize its inhibitory mechanisms at the
molecular level.
We have focused on our cryo-EM structural studies of
ligand-bound eukaryotic 20S proteasomes and how these have
identified advantages in using cryo-EM to study ligand-
binding interactions, aiming at the development of new
improved therapeutic drugs, in particular antimalarials. More
generally, the recent advances in the cryo-EM field have
changed the overall perception of its use for the detailed study
of intricate protein structures, which has been accompanied by
an increased interest in its application in drug discovery and
development (Subramaniam et al., 2016; Merino & Raunser,
2017). While in our studies of eukaryotic 20S proteasomes we
used ligands that covalently bind specific proteolytic active
sites, the utility of cryo-EM to also study noncovalent protein–
ligand interactions has been shown by others (Merk et al.,
2016). Examples of other high-resolution cryo-EM structures
with resolved densities for exogenous ligands include those of
ribosomes (Wong et al., 2014; Fischer et al., 2015; Myasnikov et
al., 2016), TRPV1 (Gao et al., 2016), p97 (Banerjee et al., 2016)
and lactate dehydrogenase (Merk et al., 2016). While cryo-EM
does not yet have the high throughput of other structural
biology methods, its advantages in the study of protein
structures and protein–ligand interactions under near-
physiological conditions have been demonstrated. These,
together with the rapid ongoing advances in cryo-EM instru-
mentation and image-analysis tools, which are both extending
the use of cryo-EM to study wider ranges of protein and
protein–ligand complexes and increasing the high resolutions
attainable (Vinothkumar & Henderson, 2016), clearly indicate
that cryo-EM will play an increasingly relevant role in struc-
tural biology and in the development of new and improved
therapeutic drugs.
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